AI Article Synopsis
- Finerenone is now part of the updated 2022 treatment guidelines for managing patients with type 2 diabetes and chronic kidney disease.
- It is considered an expensive medication compared to standard treatments.
- Patients may need to get prior authorization from their insurance before receiving this prescription.
Article Abstract
The use of finerenone is now included in the 2022 revision to standard treatment guidelines for patients with type 2 diabetes and chronic kidney disease.Finerenone is a costly addition to standard treatment. Patients may need to receive prescription preauthorization from their insurer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NAJ.0000933932.29825.ee | DOI Listing |
Publication Analysis
Top Keywords
treatment guidelines
8
type diabetes
8
diabetes chronic
8
chronic kidney
8
standard treatment
8
finerenone treatment
4
guidelines type
4
kidney disease
4
disease finerenone
4
finerenone included
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!